ITGAM and neoplasm: In this analysis, no significant change in tissue CD16−/CD11b+ MDSCs between stage II (1.94 ± 0.63, n = 9) and stage III patients (1.77 ± 0.6, n = 14, P = 0.64; Supplemental Figure 2B) was found, suggesting that in LARC, MDSCs might correlate with tumor size, but less with local spread.